Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 04 May 2018
At a glance
- Drugs RAAV2 ND4 (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Therapeutic Use
- 28 Apr 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2019.
- 28 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Dec 2017 Design keyword has changed from double-blind to open label.